LevyG.: Concluding Remarks at First International Symposium on Biopharmaceutics and Pharmacokinetics, Smolenice, Czechoslovakia, Nov. 2–4, 1970.
2.
WagnerJ. G.: Biopharmaceutics; Absorption Aspects, J. Pharm. Sci.50: 359, 1961.
3.
ZathureckyaL.: Neue Internationale Bestrebungen zur Biopharmazie und Pharmakokinetik, Pharm. Ind.36: 953–955, 1974.
4.
Editorial article: Symposium on Biopharmacy and Pharmacokinetics, Smolenice Castle, Bratislava, from 20 to 24 May 1974, Bulletin d' Information FIP No. 4: p. 6–8, 1974.
5.
WagnerJ. G.: Fundamentals of Clinical Pharmacokinetics, Drug Intelligence Publications, Hamilton, Illinois1975.
6.
RitschelW. A.: Handbook of Basic Pharmacokinetics, Drug Intelligence Publications, Hamilton, Illinois62341, 1976.
Drug Bioequivalence Study Panel: Drug Bioequivalence, A Report from the Drug Bioequivalence Study Panel to the Office of Technology Assessment (OTA), Congress of the USA, Washington, D.C., 1974.
9.
Pharmacopoea Bohemoslovenica, Editio III, Avicenum, Prague, 1970.
FeldmannE. G.: Biopharmaceutics and Drug Standards, Am. J. Hosp. Pharm.25: 110–119, 1968.
13.
BallardB. E.: Teaching at the University of California, Am. J. Pharm. Ed.32: 938, 1968.
14.
WagnerJ. G.: Pharmacokinetics, Ann. Rev. Pharmacol.8: 67–94, 1968.
15.
HirtzJ.: Letter of July 9, 1975 in response to the author's request for appropriate definition.
16.
Report of a WHO Study Group: Clinical Pharmacology; Scope, Organization, Training, WHO Report Series No. 446, Geneva, 1970.
17.
OserB. L.MelnickD.HochbergM.: Physiological Availability of the Vitamins, Study of Methods for Determining Availability in Pharmaceutical Products, Ind. Eng. Chem. Anal. Ed.17: 401–411, 1945.
18.
Symposium on Formulation Factors Affecting the Therapeutic Performance of Drug Products, Washington, D.C. March 31-April 2, 1969, Drug Intell. Clin. Pharm.3: 287–289 (Oct.) 1969.
19.
BrodieB. B.HellerW. M.: Bioavailability of Drugs, S. Karger-Basel, München, Paris, London, Sidney, 1972.
20.
Guidelines for Biopharmaceutical Studies in Man, Am. Pharm. Assoc. Acad. Pharm. Sciences, Washington, D.C., 1972.
21.
Bioavailability of Drugs; Principles and Problems, WHO Report Series No. 536, Geneva, 1974.
22.
ZathureckyaL.: 2nd International Symposium on Biopharmaceutics and Pharmacokinetics, Smolenice, May 20–24, 1974, Farm. Obzor (Bratislava)43: 529–538, 1974.
23.
Secundum Symposium cum Participatione Internationali de Biopharmacia et Pharmacokinesi, Smolenice, Diebus 20–24, Mensis Maii 1974. Internal Information of the Board of Pharmaceutical Sciences of the FIP, 1974.
24.
WagnerJ. G.: Letter of July 28, 1975 in response to the author's request for appropriate definition.
WagnerJ. G.: Design and Data Analysis of Biopharmaceutical Studies in Man, Paper presented at the 113th Annual Meeting, Am. Pharm. Assoc. Dallas, April 25–29, 1966.
SpeiserP.: Letter of July 4, 1975 in response to the author's request for appropriate definition.
29.
LevyG.: Orientation to Clinical Pharmacokinetics, In Clinical Pharmacokinetics — A Symposium, Am. Pharm. Assoc. Acad. Pharm. Sci. 1–9, 1974.
30.
SwintoskyJ. V.: Newer Developments in Clinical Education and Practice of Pharmacy in Various Countries, Paper presented at the 36th Int. Congress of Pharm. Sci. FIP, Warsaw, September 6–10, 1976.
31.
The United States Pharmacopeia, XVIIth Revision, Mack Publishing Co., Easton, 1965.